Thumbnail Image
Item

p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab

Vici, P
; 
Sperati, F
; 
Maugeri-Saccà, M
; 
Melucci, E
; 
Benedetto, AD
; 
Lauro, LD
; 
Pizzuti, L
; 
Sergi, D
; 
Terrenato, I
; 
Esposito, L
... show 7 more
Citations
Altmetric:
Genre
Journal Article
Date
2014-01-01
Advisor
Committee member
Group
Department
Subject
p53 status
 fasting glucose
 HER2 positive breast cancer
 trastuzumab
Permanent link to this record
http://hdl.handle.net/20.500.12613/5329
Collections
Faculty/Researcher Works
Show all metadata
Files
Thumbnail Image
p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non dia.pdf
Adobe PDF, 852.97 KB
Research Projects
Organizational Units
Journal Issue
DOI
10.18632/oncotarget.2060
Abstract
Mounting evidence supports the role of p53 in metabolic processes involved in breast carcinogenesis. We investigated whether p53 status affects the association of pre-treatment fasting glucose with treatment outcomes in 106 non diabetic, HER2 positive breast cancer patients treated with trastuzumab. p53 status was validated against gene sequencing of selected codons in 49 patients. The Kaplan-Meier method and log rank test were used to compare survival by categories of fasting glucose in the overall population and separate settings. Cox models included age and body mass index. Direct sequencing confirmed the lack of mutations in 73.7% of p53 negative patients and their presence in 53.3% of p53 positive cases. At 66 months, 88.3% of patients with glucose ≤ 89.0 mg/dl (median value) did not experiment disease progression compared with 70.0% in the highest category (p=0.034), with glucose being an independent predictor (p=0.046). Stratified analysis confirmed this association in p53 negative patients only (p=0.01). In the early setting, data suggested longer disease free survival in p53 negative patients in the lowest glucose category (p=0.053). In our study, p53 status acted as effect modifier of the investigated association. This may help differentiate target sub-groups and affect outcomes interpretation in similarly characterized patients.
Description
Citation
Citation to related work
Impact Journals, LLC
Has part
Oncotarget
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
Embedded videos